A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Robinul Warnings, Precautions, Pregnancy, Nursing, Abuse - Glycopyrrolate
Robinul Warnings, Precautions, Pregnancy, Nursing, Abuse - Glycopyrrolate
WARNINGS
This drug should be used
with great caution, if at all, in patients with glaucoma
or asthma.
In the Ambulatory Patient
Glycopyrrolate may produce drowsiness
or blurred vision. The patient should be cautioned regarding activities
requiring mental alertness
such as operating a motor
vehicle or other machinery
or performing hazardous work while taking this drug. In
addition, in the presence of a high environmental temperature, heat
prostration (fever
and heat stroke
due to decreased sweating) can occur with use of glycopyrrolate
injection.
Diarrhea may be an early symptom
of incomplete intestinal
obstruction, especially in patients with ileostomy or colostomy.
In this instance treatment
with glyclopyrrolate injection
would be inappropriate and possibly harmful.
PRECAUTIONS
General
Investigate any tachycardia
before giving glycopyrrolate
since an increase in the heart
rate may occur.
Use with caution in patients with: coronary artery disease;
congestive heart failure; cardiac
arrhythmias; hypertension; hyperthyroidism.
In managing ulcer patients,
use glycopyrrolate
injection with caution
in the elderly and in all patients with autonomic
neuropathy, hepatic
or renal disease, ulcerative
colitis or hiatal hernia,
since anticholinergic drugs may aggravate these conditions.
With overdosage, a curare-like action
may occur.
Drug Interactions
The intravenous
administration
of any anticholinergic
in the presence of cyclopropane
anesthesia can result
in ventricular arrhythmias;
therefore, caution should be observed if glycopyrrolate
injection is used
during cyclopropane anethesia. If the drug
is given in small incremental doses of 0.1 mg
or less, the likelihood of producing ventricular
arrhythmias is reduced.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have not been performed to evaluate
carcinogenic potential. In
the teratology studies, diminished rates of conception
and of survival at
weaning were observed in rats, in a dose-related manner. Studies
in dogs suggest that this may be due to diminished seminal
secretion which is evident at high doses of glycopyrrolate.
Pregnancy Category B
Reproduction studies have been performed in rats and rabbits up
to 1000 times the human
dose and have revealed
no teratogenic effects
from glycopyrrolate. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal
reproduction studies
are not always predictive of human response, this drug
should be used during pregnancy only if clearly needed.
Nursing Mothers
It is not known whether this drug
is excreted in human milk.
Because many drugs are excreted in human
milk, caution should be exercised when glycopyrrolate injection
is administered to a nursing
woman.
Pediatric Use
Safety and effectiveness
in children below the age
of 12 years have not been established for the management of peptic
ulcer.
top
